PDSB News and Press, PDS Biotechnology Corporation

Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial PRINCETON, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq...

2024-04-22 14:20:23 ET Summary Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design.  A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation of approximately $72.53.  Positive data ...

2024-03-27 12:17:02 ET PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Conference Call March 27, 2024 08:00 a.m. ET Company Participants Dr. Frank Bedu-Addo - Chief Executive Officer Lars Boesgaard - Chief Financial Officer Dr. Kirk Shepard - Chief Medical ...

2024-03-27 07:31:30 ET More on PDS Biotechnology PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk Seeking Alpha’s Quant Rating on PDS Biotechnology ...

Unique mechanism of action of the combination of PDS01ADC and Versamune ® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC,...

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...

2024-03-26 13:47:57 ET More on PDS Biotechnology PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk Seeking Alpha’s Quant Rating on PDS Biotechnology ...

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines ba...

2024-03-13 10:55:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are not for investors with a low-risk tolerance. This sector has stocks that are either considered blue-chip names or pre-revenue lotto tickets. It is also one of the most im...

Preclinical research published in Vaccines demonstrates Infectimune ® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants Patent for composition of matter and use of Infectimune ® based...